Latest Johnson & Johnson News & Updates

See the latest news and media coverage for J&J. We track all announcements, press releases, and industry mentions in real time, all in one place.

Johnson & Johnson (J&J)

Multinational healthcare company

jnj.com

Headquarters: New Brunswick, United States
Company type: Public company
Number of employees: 100,000+
Industry: Pharmaceuticals

Last updated Today

Latest news about Johnson & Johnson (J&J)

In short: J&J reported strong Q2 2026 earnings, raised its full-year outlook, and advanced several oncology and rare disease clinical programs.

Company announcements

July 30 J&J

J&J's RYBREVANT FASPRO receives FDA Priority Review for head and neck cancer

It targets EGFR and MET, with 42% overall response rate and one-third complete responses in a pivotal study

July 29 J&J

J&J completes acquisition of Firefly Bio for $1 billion

The acquisition broadens its capabilities in targeting hard-to-treat cancers and adds a novel degrader antibody conjugate platform.

July 29 J&J

J&J collaborates with Sail Biomedicines on in vivo CAR-T

The partnership targets immune-mediated diseases with a platform to generate CAR-T therapies within the body, including an option to acquire Sail for $2.58 billion.

July 27 J&J

J&J announces a proposed resolution of ovarian talc litigation

Conditioned on 95% participation, it involves a $5.5 billion commitment with payments starting in 2027.

Media coverage

Yesterday Simply Wall St

Johnson & Johnson (JNJ) Makes Three Big Oncology Moves In A Week - Simply Wall St News

These steps may influence how investors ... mean for risk, timelines and portfolio balance for NYSE:JNJ holders. Stay updated on the most important news stories...

July 30 Yahoo Finance

J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout

Johnson & Johnson (J&J) is venturing further into the increasingly crowded in vivo CAR-T market, this time through an autoimmune drug development and potential acquisition...

July 30 Seeking Alpha

J&J granted FDA priority review for Rybrevant Faspro in head and neck cancer

Johnson & Johnson's (JNJ) wins FDA priority review for bid to expand the label for its cancer therapy Rybrevant Faspro developed with Halozyme (HALO). Read...

July 30 PR Newswire

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) recei...

/PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental...

Never miss news about J&J

Track J&J and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

J&J competitors & trending companies

Browse news for competitors to J&J and other trending companies.